{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089068","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.345373+00:00","generated_at":"2026-05-31T09:15:41.410709+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track","bullets":["Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.","Operating loss narrowed 48% to $3.4M from $6.6M; additional cost cuts expected to save $5M annually.","CFO Kathleen Bloch retired; Peter Mariani appointed as new CFO effective August 14, 2024.","On track to submit DrugSorb-ATR marketing applications to U.S. FDA and Health Canada this quarter.","Secured $20M credit facility with Avenue Capital; cash and restricted cash $14.9M as of June 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089068","json":"https://secwatch.observer/filing/0001104659-24-089068.json","markdown":"https://secwatch.observer/filing/0001104659-24-089068.md","text":"https://secwatch.observer/filing/0001104659-24-089068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/0001104659-24-089068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924089068/tm2421554d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:15:41.410709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}